Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission ...

Successful management of denture-associated candidiasis relies heavily on mechanical disinfection rather than pharmacologic ...

Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete ...

Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could ...

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvem ...

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn ...

Arrowhead (ARWR) announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA ...

Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.

A single dose of intravenous (IV) iron dextran is the cost-effective treatment for women with heavy menstrual bleeding and ...

Arrowhead Pharmaceuticals, Inc. today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being ...